«ÉÏһƪ/Previous Article|±¾ÆÚĿ¼/Table of Contents|ÏÂһƪ/Next Article»

ÖлªÈéÏÙ²¡ÔÓÖ¾£¨µç×Ӱ棩[ISSN:1674-0807/CN:11-9146/R]

¾í:

µÚ4¾í

ÆÚÊý:

2010Äê5ÆÚ

Ò³Âë:

521-529

À¸Ä¿:

×ÛÊö

³ö°æÈÕÆÚ:

2010-10-01

ÎÄÕÂÐÅÏ¢/Info

×÷Õß:

Kentaro;Tamaki;Hironobu;Sasano

Department of Surgical Oncology, Tohoku University Graduated School of Medicine, Miyagi Japan (Kentaro Tamaki); Department of Pathology, Tohoku University School of Medicine, Miyagi Japan (Kentaro Tamaki, Hironobu Sasano)

¹Ø¼ü´Ê:

Breast neoplasms; Vascularity; Neovascularization; Surgical pathology; Materials

ÕªÒª:

Breast cancer is one of the most common malignancies among women and its morbidity has recently increased in many parts of the world. Numerous factors have been reported to be associated with development of breast cancer including angiogenesis. Angiogenesis or the formation of new blood vessel networks, not only plays a pivotal role in human normal development, but also in pathophysiological conditions such as inflammatory diseases and neoplasms, which consists of multiple coordinated, sequential and interdependent steps. The angiogenic program requires the degeneration of the basement membrane, endothelial cells migration and invasion of the extracellular matrix, with endothelial cell proliferation and capillary lumen formation before maturation and stabilization of the new vasculature. Results of previous studies demonstrated that normal breast adjacent to malignant breast induced angiogenesis twice as frequently as did tissues from nonª²neoplastic breast, suggesting that the angiogenic switch occurs before morphological changes are discernible. In addition, angiogenesis precedes, and is considered to be required for tumor progression and metastasis. When a new tumor reaches the size of 1-2 mm, its growth requires the induction of new blood vessels, which may consequently lead to the development of metastases, via the penetration of malignant cells into the circulation. The term ¡°angiogenic switch¡± describes a hallmark of malignancy, in which the tumor initiates recruitment of its own blood supply by shifting the balance between stimulatory and inhibitory factors of angiogenesis. Numerous studies have been reported on the mechanisms of control or regulation of angiogenesis since the discovery of endothelial growth factor (VEGF) and angiopoetin family proteins. Other molecules involved in this process of angiogenesis, including pigment epithelium derived factor (PEDF), platelet factor 4, angiostatin and endostatin, have been proposed as angiogenesis inhibitors. In addition, the protein called vasohibin has been very recently demonstrated, one of the first established negative feedback regulators of angiogenesis. As for antiangiogenic therapy, antiangiogenic trials are under investigation in the adjuvant setting and antiangiogenic agents may be incorporated into the standard therapy of breast cancer treatment in the near future. In that case, it should become very important to evaluate the status of vascularity or neovascularization in the patients with breast carcinoma. This brief review article summarizes the analysis of vascularity and neovascularization in surgical pathology materials of breast carcinoma and its clinical significance.

³£Óù¦ÄÜ

¸üÐÂÈÕÆÚ/Last Update: 2010-01-20